Q2 2025 Spero Therapeutics Inc Earnings Call Transcript

Aug 12, 2025 / 08:30 PM GMT

Release Date Price: €1.85

Transcript 10-Q8-K

Key Points

Positve

The phase 3 Pivot PO trial for tepipenem HBR in complicated urinary tract infections (CUTIs) met its primary endpoint and was stopped early for efficacy.
Tepipenem HBR demonstrated non-inferiority to intravenous imipenem cilastatin in hospitalized adult patients with CUTIs, including pyelonephritis.
The trial's early stopping for efficacy resulted in meaningful cost savings, extending Spero Therapeutics Inc (SPRO)'s cash runway into 2028.
Spero Therapeutics Inc (SPRO) reported an increase in total revenue for Q2 2025 to $14.2 million, up from $10.2 million in Q2 2024, primarily due to collaboration revenue from GSK.
The company achieved a significant reduction in R&D expenses, from $23.7 million in Q2 2024 to $10.7 million in Q2 2025, due to reduced clinical expenses related to the Pivot PO study.

Negative

The SPR 720 program did not meet its primary endpoint in a phase 2A proof of concept study for non-tuberculous mycobacterial pulmonary disease.
Potential dose-limiting safety signals were observed in the SPR 720 study, including cases of reversible grade 3 hepatotoxicity.
Spero Therapeutics Inc (SPRO) reported a net loss of $1.7 million for Q2 2025, although this was an improvement from a $17.9 million loss in Q2 2024.
General and administrative expenses increased to $5.9 million in Q2 2025 from $5.5 million in Q2 2024, primarily due to increased personnel and professional services expenses.
The FDA action on the regulatory filing for tepipenem HBR is not expected until the second half of 2026, indicating a lengthy approval process.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SPRO.OQ - Spero Therapeutics Inc
Q2 2025 Spero Therapeutics Inc Earnings Call
Aug 12, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Spero Therapeutics Second quarter 2025 earnings conference call.

At this time, all participants are in the less only mode.

Following the company's formal remark, we will open up the call for questions.

Please be advised that this call is being recorded and a replay will be available.

You can find the information in the replay and further information related to today's announcement on the Spiro Therapeutics website at www.spirotherapeutics.com.

At this time, I would like to turn the call over to Shai Bran, senior director Investor Relations. Mr. Bran, please go ahead.

------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.